Anti-EGFR-modified nanoparticles and folate-functionalized carriers have been effectively utilized to deliver siRNA or mRNA to suppress tumor growth, demonstrating improved outcomes in HCC models. This evidence concerns the gene EGFR and hepatocellular carcinoma.